Divalproex Sodium Tablet, Delayed Release
Product Images NDC 55111-530

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55111-530). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1

Packaging label for Divalproex Sodium Delayed-Release Tablets USP, 125 mg, manufactured by Dr. Reddy's Laboratories Limited. The label indicates a package size of 100 tablets (10 x 10 unit-dose). The label includes instructions for pharmacists to dispense with an accompanying Medication Guide and states the product is Rx only. Storage and safety warnings are also present.*

FDA Label Image

Carton2

Packaging label for divalproex sodium delayed-release tablets USP, 250 mg, by Dr. Reddy's Laboratories Limited. The label shows the product name, strength, dosage form, and quantity (100 tablets, 10 x 10 unit-dose). It includes storage instructions, a pharmacist warning to dispense with the Medication Guide, and manufacturer details from India. The design features blue and red text on a white background with the Dr. Reddy's logo.*

FDA Label Image

Carton3

Packaging label for divalproex sodium delayed-release tablets USP, 500 mg, oral dosage form. The label shows the product name, strength, and form prominently with dosage instructions and pharmacist dispensing guidance. Manufactured by Dr. Reddy's Laboratories Limited, it contains 100 tablets in unit-dose blister packs (10 blister packs each containing 10 tablets). The label includes storage instructions and a warning that the package is not child resistant.*

FDA Label Image

Container1

Label for Divalproex Sodium delayed-release tablets USP, 125 mg, by Dr. Reddy's Laboratories Limited. The label indicates the package contains 100 tablets and lists the NDC 55111-529-01. It includes handling instructions, storage conditions, and a barcode, with a prominent warning for pharmacists to dispense with an accompanying medication guide.*

FDA Label Image

Container2

Label for divalproex sodium delayed-release tablets USP, 250 mg, manufactured by Dr. Reddy's Laboratories Limited. The label states a package count of 100 tablets and highlights pharmacist instructions to dispense with the medication guide. It includes dosage strength, NDC 55111-530-01, and regulatory information such as storage conditions and warnings about the seal.*

FDA Label Image

Container3

Label for Divalproex Sodium delayed-release tablets, 500 mg, by Dr. Reddy's Laboratories Limited. The label indicates a package of 100 tablets with NDC 55111-531-01. It includes instructions for pharmacists and storage information, emphasizing this is a prescription drug with valproic acid activity.*

FDA Label Image

Figure1 (Figure1)

A bar chart comparing percentage values in two studies labeled Study 1 (YMRS) and Study 2 (MRS). Each study compares results for PBO (placebo) and DVPX (divalproex sodium), showing higher percentages for DVPX in both studies compared to placebo. The y-axis is labeled from 0% to 70%.*

FDA Label Image

Fiigure2 (Figure2)

A cumulative distribution plot showing the percentage reduction in CPS rate among patients treated with divalproex sodium compared to placebo. The graph plots percent reduction in CPS rate on the vertical axis against the percentage of patients on the horizontal axis, highlighting improvement and worsening trends for each group.*

FDA Label Image

Figure3

A cumulative percentage plot showing the percent reduction in CPS Rate compared to the percent of patients for divalproex sodium tablets at high and low doses. The vertical axis represents percentage reduction from -100% (worsening) to +100% (improvement), with a zero baseline indicating no change. The horizontal axis indicates the percentage of patients from 0 to 100%. Two lines are visible: a solid line for high dose and a dashed line for low dose.*

FDA Label Image

Figure4 (Figure4)

A bar chart comparing results between placebo and divalproex sodium groups in two separate studies, labeled Study 1 and Study 2. The vertical axis represents a measured variable with values ranging from 0 to 6, showing higher values for placebo in both studies compared to divalproex sodium.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of the active ingredient divalproex sodium, showing its molecular arrangement including carbon chains, carboxyl groups, and sodium ions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.